Unique Pharmacological Properties
THC is unique in its ability to convert into 11-hydroxy-THC, a metabolite that enhances its psychoactive effects. This conversion occurs primarily in the liver during first-pass metabolism, which is why oral consumption of THC results in a delayed but prolonged effect compared to inhalation.
Current Clinical Trials
Recent clinical trials have explored THC’s potential beyond recreational use. One study is investigating THC’s efficacy in managing chronic low back pain, highlighting its analgesic properties. Another trial is examining THC’s role in reducing spasticity in multiple sclerosis, a condition characterized by muscle stiffness and spasms.
Future Healthcare Potential
The future of THC in healthcare looks promising, particularly in pain management and neurodegenerative diseases. Its ability to modulate pain and inflammation makes it a candidate for treating conditions like arthritis and fibromyalgia. However, the psychoactive effects of THC pose challenges, necessitating careful dosing and monitoring in therapeutic settings. As research progresses, THC could become a cornerstone in cannabinoid-based therapies, provided its psychoactive effects are managed effectively.
THC Molecule
THC for Clinical Trials – GMP Compliance
THC for Clinical Trials - GMP Compliance The U.S. Food and Drug Administration (FDA) regulates pharmaceutical cannabinoids like THC under the same rigorous standards as any […]
Nabilone and Veteran PTSD: Canadian Evidence Led the Way
Nabilone and Veteran PTSD: Canadian Evidence Led the Way In Canada, the use of cannabinoids for therapeutic purposes has been backed by some of the most […]
Advances in Cannabinoid Research for Veteran Health
For Veterans: Understanding the Endocannabinoid System and Key Cannabinoids Veterans are using cannabis products, but many have questions. Cannabinoids are compounds that interact with the body's […]
The Distrio Network
The Distrio Network is a content hub for procurement, quality assurance, and technical professionals in the global cannabinoid supply chain. Built using DistrioGPT, with cannabinoid-specific websites delivering blogs, guest stories, and deep dives on the latest research, cannabis-focused professionals will find in-depth and engaging content about these molecules and their markets.
CBD: The Therapeutic Non-Psychoactive Cannabinoid
Cannabidiol (CBD) is a non-psychoactive cannabinoid that has gained popularity for its potential therapeutic benefits. Unlike THC, CBD does not produce a high, making it appealing for medical use. It interacts with various receptors in the body, notably enhancing the activity of serotonin 1A receptors, which contributes to its anxiolytic (anxiety-reducing) effects. CBD’s low oral bioavailability (~6%) is due to its extensive first-pass metabolism. Clinically, CBD has been shown to reduce seizure frequency in epilepsy, particularly in conditions like Dravet syndrome. Ongoing research continues to explore its efficacy in treating anxiety disorders, chronic pain, and inflammation.
CBG: The Emerging Cannabinoid
Cannabigerol (CBG) is a lesser-known, non-psychoactive cannabinoid that is gaining attention for its potential health benefits. CBG is unique because it acts as a precursor to other cannabinoids, including THC and CBD. This means that during the cannabis plant’s growth, CBG is converted into these more prevalent cannabinoids. CBG is being studied for its anti-inflammatory and neuroprotective properties, with early research suggesting it may be beneficial for conditions like inflammatory bowel disease and glaucoma. Although clinical trials are limited, the ongoing research into CBG’s pharmacological effects is promising, highlighting its potential as a therapeutic agent without psychoactive effects.
THC: The Psychoactive Cannabinoid
Tetrahydrocannabinol (THC) is the most well-known cannabinoid, primarily responsible for the psychoactive effects of cannabis. When consumed, THC is rapidly absorbed into the bloodstream, especially when inhaled, with a bioavailability ranging from 10-35%. This means that a significant portion of THC enters the bloodstream and reaches the brain, where it binds to CB1 receptors, producing the characteristic “high.” A unique aspect of THC is its conversion into 11-hydroxy-THC, a metabolite that enhances its psychoactive effects, through the liver. Beyond its recreational use, THC is being studied in clinical trials for its potential to alleviate chronic pain and spasticity associated with multiple sclerosis. These trials aim to harness THC’s analgesic properties while managing its psychoactive effects.
Contact Us
